Table 3.

Most frequently reported^a AEs during 3 months of nightly treatment with transdermal rotigotine in the safety population (n = 81).

Adverse event	Number (%) of patients
	Overall	Relation to treatment
		Probable	Possible
Nausea	7 (8.6)	6 (7.4)	1 (1.2)
Anxiety	3 (3.7)	3 (3.7)	0
Restlessness	3 (3.7)	2 (2.5)	1 (1.2)
Dizziness	3 (3.7)	1 (1.2)	2 (2.5)
Pain	2 (2.5)	2 (2.5)	0
Rash	2 (2.5)	2 (2.5)	0
Vomiting	2 (2.5)	1 (1.2)	1 (1.2)

^aReported by at least 2 patients overall; patients could report ≥1 AE.